相关实验视频
Updated: Jul 27, 2025

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.9K
与一般人口相比,澳大利亚痴呆症患者的糖尿病治疗减强:一项全国性队列研究
Leonie J Picton1, Johnson George1,2, J Simon Bell1
1Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Journal of the American Geriatrics Society
|June 9, 2023
概括
痴呆症的诊断可能会改变糖尿病护理目标. 这项研究发现,启动痴呆症药物治疗并没有触发糖尿病治疗的减少,这表明痴呆症患者可能被过度治疗.
科学领域:
- 老年学是指老年学的学科.
- 药理学 药理学 是一个学科.
- 公共卫生 公共卫生
背景情况:
- 痴呆症诊断可以改变护理优先级,可能导致放松糖尿病管理目标.
- 在糖尿病患者中,这可能涉及降低药物强度.
研究的目的:
- 在开始服用痴呆症特异性药物之前和之后,调查痴呆症患者糖尿病药物使用的变化.
主要方法:
- 一项全国性队列研究利用了澳大利亚药物索赔数据.
- 基于组的轨迹建模 (GBTM) 分析了24个月的糖尿病药物使用 (定义的每日剂量).
- 将痴呆症队列 (N=1884) 与匹配的一般人口队列 (N=7067) 进行比较.
主要成果:
- 16.5%的痴呆症患者和24.0%的普通人群显示糖尿病药物的减强.
- 在一般人口群体中,缓解压力更为普遍.
- 在痴呆症队列中,减强与稍大一些的年龄和更高的并发症负担有关.
结论:
- 开始服用痴呆症药物似乎并没有减少糖尿病治疗强度.
- 与一般人群相比,患有痴呆症的人不太可能减轻糖尿病药物的强度.
- 研究结果表明,在患有痴呆症的人群中,糖尿病的过度治疗有可能存在.
相关概念视频
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Diabetes: Symptoms, Diagnosis, and Complications
605
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
605
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Insulin: Dosing Regimen and Adverse Effects
216
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
216
Alzheimer's Disease: Treatment
224
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
224

